This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary and join the 2,438 subscribers getting it for FREE every day!
The Killer B’s: Biotechs and Banks
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]
Biotech shares are testing support levels, as measured by the NASDAQ Biotech ETF ($IBB) at roughly $336. The chart below shows how the ETF has been hugging that support line, and just how critical it is. A breakdown in the biotech sector would likely send the group lower towards $328, which is undoubtedly not a disaster, but it would be a bump in the road and suggest one of two things. Either the market is becoming risk adverse, or the money is rotating into another sector.
The group’s struggles start at the top, with shares of Celgene ($CELG) struggling since the significant Morgan Stanley downgrade on October 5. For now, the stock seems to be finding support around $136.
Amgen shares seem to be showing signs of life again, after a small pullback.
Gilead also doesn’t look in too bad of shape.
These three stocks, each have nearly an 8 percent weighting in the IBB ETF, and Biogen does too. The big four biotech stocks have roughly a 32 percent weighting in the ETF, so the group is likely going nowhere if these four stock do not get their acts together.
It likes they may be regrouping and getting ready for the next push up.
Financials seem to be benefitting the greatest, and the group is getting set to rise even further. The current trading pattern in shares of the Financial Select Sector SPDR ETF ($XLF) has a nearly perfect pennant /flag formation in it, which means that the ETF is likely to move higher, soon.
Bank of America has completely broken out and is now trading at levels not seen in nearly a decade. It may seem crazy, but shares of Bank Of America could be headed back towards $40, a rise of almost 51 percent from current levels around $26.50
Mott Capital Management uses a long-term thematic growth approach to investing in equities. We search for investments that both reflect and help to shape…
Netflix may have found bottom too, after its post-earnings slump. It sure looks like it did.
Short-term interest rates are starting to rise, and that means the market is preparing for the next Fed rate hike. Three-month US Dollar Libor is at its highest level in nearly a decade!
Free Articles From Mike:
We offer a lot of great commentaries all week talking about the major an relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]\
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.